SeraGene Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 17

SeraGene Therapeutics General Information

Description

Developer of ribonucleic acid-based therapeutics designed to provide long-lasting control over coagulation disorders. The company offers liver-targeted RNA agents, nanomedicine delivery systems, and a diversified preclinical pipeline, enabling healthcare providers to manage bleeding and thrombotic conditions with reduced treatment burden and improved safety for underserved patient populations.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2405 Wesbrook Mall
  • 4th floor
  • Vancouver, British Columbia V6T 1Z3
  • Canada
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 2405 Wesbrook Mall
  • 4th floor
  • Vancouver, British Columbia V6T 1Z3
  • Canada

SeraGene Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SeraGene Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Accelerator/Incubator 01-Jan-2026 Completed Pre-Clinical Trials
10. Early Stage VC 20-Nov-2025 Completed Pre-Clinical Trials
9. Seed Round Completed Pre-Clinical Trials
8. Accelerator/Incubator 20-Aug-2025 Completed Pre-Clinical Trials
7. Accelerator/Incubator 24-Jan-2025 Completed Pre-Clinical Trials
6. Accelerator/Incubator 05-Dec-2024 Completed Pre-Clinical Trials
5. Accelerator/Incubator 24-Oct-2024 Completed Pre-Clinical Trials
4. Accelerator/Incubator 01-Jan-2024 Completed Pre-Clinical Trials
3. Accelerator/Incubator Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
To view SeraGene Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SeraGene Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SeraGene Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
WBL Fellows Program Accelerator/Incubator
Pathway to Cures Not-For-Profit Venture Capital Minority
Life Sciences BC Accelerator/Incubator
HATCH Venture Builder Accelerator/Incubator
adMare Bioinnovations Corporation
You’re viewing 5 of 17 investors. Get the full list »

SeraGene Therapeutics FAQs

  • When was SeraGene Therapeutics founded?

    SeraGene Therapeutics was founded in 2022.

  • Where is SeraGene Therapeutics headquartered?

    SeraGene Therapeutics is headquartered in Vancouver, Canada.

  • What is the size of SeraGene Therapeutics?

    SeraGene Therapeutics has 7 total employees.

  • What industry is SeraGene Therapeutics in?

    SeraGene Therapeutics’s primary industry is Biotechnology.

  • Is SeraGene Therapeutics a private or public company?

    SeraGene Therapeutics is a Private company.

  • What is SeraGene Therapeutics’s current revenue?

    The current revenue for SeraGene Therapeutics is .

  • How much funding has SeraGene Therapeutics raised over time?

    SeraGene Therapeutics has raised $3K.

  • Who are SeraGene Therapeutics’s investors?

    WBL Fellows Program, Pathway to Cures, Life Sciences BC, HATCH Venture Builder, and adMare Bioinnovations are 5 of 17 investors who have invested in SeraGene Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process